What is claimed is:

1. A pharmaceutical aerosol formulation which comprises:

(i) fluticasone propionate and

(ii) a hydrofluoroalkane (HFA) propellant,

characterised in that the fluticasone propionate is completely dissolved in the formulation.

2. A pharmaceutical formulation according to claim 1 which comprises:

(i) fluticasone propionate;

(ii) a hydrofluoroalkane (HFA) propellant;

(iii) a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler; and

(iv) a solubilisation agent in sufficient quantity to solubilise the fluticasone propionate in the formulation.

3. A pharmaceutical formulation according to claim 1 wherein the hydrofluoroalkane (HFA) propellant is 1,1,1,2-tetrafluoroethane (HFA134a).

4. A pharmaceutical formulation according to claim 1 containing a low volatility component which is glycerol, propylene glycol or polyethylene glycol.

5. A pharmaceutical formulation according to claim 4 containing a low volatility component which is polyethylene glycol.

6. A pharmaceutical formulation according to claim 4 containing a low volatility component which is glycerol.

7 A pharmaceutical formulation according to claim 4 wherein the low volatility component is present at a concentration of 0.5 to 3% w/w.

8. A pharmaceutical formulation according to claim 1 which compris s:

(i) fluticasone propionate;

(ii) 1,1,1,2-tetrafluoroethane (HFA 134a);

(iii) 0.5-3% (w/w) glycerol; and

(iv) a solubilisation agent in sufficient quantity to solubilise the fluticasone propionate in the formulation.

9. A pharmaceutical formulation according to claim 1 which contains between 0.8 and 1.6% (w/w) glycerol.

10. A pharmaceutical formulation according to claim 9 which contains between 1.0 and 1.6% (w/w) glycerol.

11. A pharmaceutical formulation according to claim 10 which contains 1.3% (w/w) glycerol.

12. A pharmaceutical formulation according to claim 10 which contains 1.0% (w/w) glycerol.

13. A formulation according to claim 1 wherein the concentration of fluticasone propionate is 0.025 to 0.15% w/v.

14. A formulation according to claim 13 wherein the concentration of fluticasone propionate is 0.035 to 0.15% w/v.

15. A formulation according to claim 14 wherein the concentration of fluticasone propionate is 0.04 to 0.1% w/v.

16. A formulation according to claim 13 wherein the concentration of fluticasone propionate is 0.025 to 0.04% w/v.

17. A formulation according to claim 1 wherein a solubilisation agent is present which is ethanol or propylene glycol.

18. A formulation according to claim 1 wherein a solubilisation agent is present which is an alkane or ether.

19. A formulation according to claim 1 wherein a solubilisation agent is present which is dimethoxymethane.

20. A formulation according to claim 1 wherein a solubilisation agent is present which is ethylacetate.

21. A formulation according to claim 17 wherein a solubilisation agent is present which is ethanol.

22. A formulation according to claim 21 wherein the concentration of ethanol is 5 to 30% w/w.

23. A formulation according to claim 22 wherein the concentration of ethanol is 10 to 20% w/w.

24. A formulation according to claim 22 wherein the concentration of ethanol is 7 to 16% w/w.

25. A formulation according to claim 22 wherein the concentration of ethanol is 7 to 11% w/w.

26. A formulation according to claim 22 wherein the concentration of ethanol is 7 to 8% w/w.

27. A formulation according to claim 19 wherein the concentration of solubilisation agent is 14 to 16% w/w.

28. A canister comprising a metering valve and containing a composition according to claim 1.

29. A canister according to claim 28 comprising an aluminium can which is anodised, lacquer-coated and/or plastic coated.

30. A canister according to claim 29 which is coated with a fluorocarbon polymer.

31. A canister according to claim 28 fitted with a metering valve of metering volume 100 μl.

32. A metered dose inhaler which comprises a canister as claimed in claim 28 fitted into a suitable channelling device.

33. A metered dose inhaler according to claim 32 wherein the channelling device comprises a mouthpiece actuator having an actuator orifice of diameter 0.25mm or less.

34. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to claim 1.

35. A formulation according to claim 20 wherein the concentration of solubilisation agent is 14 to 16% w/w.

36. A formulation according to claim 14 wherein the propellant is 1,1,1,2-tetrafluoroethane and a solubilising agent is present which is ethanol.

37. A formulation according to claim 15 wherein the propellant is 1,1,1,2-tetrafluoroethane and a solubilising agent is present which is ethanol.

38. A formulation according to claim 36 wherein a low volatility to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler component is present which is glycerol at a concentration of 0.5-3% w/w.

39. A formulation according to claim 37 wherein a low volatility to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler component is present which is glycerol at a concentration of 0.5 -3% w/w.